Recruitment

Recruitment Status
Completed
Estimated Enrollment
60

Summary

Conditions
  • Hemophilia A
  • Hemophilia B
Type
Observational
Design
Observational Model: CohortTime Perspective: Prospective

Participation Requirements

Age
Between 21 years and 125 years
Gender
Both males and females

Description

There are two groups (cohorts) in this study. One group is adult men with congenital hemophilia A or B who qualify for the study. The other group is their spouse or significant other (SSO) who are voluntarily identified by the person with congenital bleeding disorder for recruitment into the study. ...

There are two groups (cohorts) in this study. One group is adult men with congenital hemophilia A or B who qualify for the study. The other group is their spouse or significant other (SSO) who are voluntarily identified by the person with congenital bleeding disorder for recruitment into the study. For the adult men with congenital hemophilia A or B, the study involves a minimum of 2 visits and includes screening, medical history and physical exam review, completing confidential questionnaires and interview. Eligible men with congenital hemophilia A or B (person with congenital bleeding disorder, PWCBD) are given the option to permit the investigator to contact their spouse or significant other (SSO) for participation in the study. If PWCBD has an SSO, the SSO is not required to participate in the study. Spouse/significant other(SSO)of men with congenital hemophilia A or B may enter the study only if they have been voluntarily identified by their partner (PWCBD) and their partner has opted to allow investigator to contact them. For the SSO who chooses to participate in the study, the study will involve a minimum of one visit and includes completing confidential questionnaires and interview. All participation including questionnaires and interview information collected is confidential and protected by health privacy information laws and records are de-identified. The study is sponsored by a grant from The National Hemophilia Foundation.

Tracking Information

NCT #
NCT01510418
Collaborators
Brigham and Women's Hospital
Investigators
Principal Investigator: Aric Parnes, MD Brigham and Women's Hospital